An acid reflux drug got recalled. Company says bottles might have different meds
One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles.
Teva Pharmaceuticals pulled lot No. 5420094 of 10 mg Metoclopramide tablets in 100-count bottles after 'a single 20 mg Torsemide tablet that does not belong was discovered in each of three individual sealed bottles of 10 mg Metoclopramide tablets.'
It comes from the Teva press release posted to the company website that the FDA apparently missed when it stated 'press release not issued for this recall' under the press release URL part of the FDA's enforcement alert.
Metoclopramide treats reflux symptoms in adults after failure of normal treatments.
'Torsemide is used to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease,' the Mayo Clinic said.
READ MORE: Broward drug company recalls 3 eye drugs that might not be sterile
The FDA classified this as a Class II recall, meaning problems caused by this mixup shouldn't last long, and there's a 'remote' chance of serious problems.
'...the likelihood of an unintended drug reaction occurrence is remote/unlikely as Metoclopramide tablets will not be dispensed in the original packaging but will be divided at the pharmacy level,' Teva said. 'and be dispensed in smaller quantities for patient use, where the difference in tablets is likely to be noticed by the pharmacist.'
'Likely' although there's not much difference in how each medication looks.
Teva says the 10 mg Metoclopramide tablets are white, round, dividing line on one side, '2203' above the divider on that side and 'TEVA' on the other side. The National Library of Medicine describes the 20 mg Torsemide tablets are white, round, dividing line on one side with '917' above the divider.
The Metoclopramide tablets are 8 millimeters in size, while the Torsemide tablets are 10 millimeters.
For instructions on how to return the recalled lot, which has an expiration date of 9/2027, go to Teva's online consumer recall letter. Direct questions about this recall to 888-838-2872, option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time to speak to a person. Voice mail works 24 hours a day.
If you have a medical problem because you think a wayward Torsemide tablet was taken by a Metoclopramide user, call a medical professional.
Then, notify the FDA MedWatch adverse event program. Third, call Teva at 888-838-2872, option 3, then option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time, or email USMedInfo@tevapharm.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation. Orphan drug designation is granted by the FDA to therapies intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as tax credits for clinical testing, waiver of certain fees and most importantly, seven years of market exclusivity upon approval. For Sanofi, this designation provides riliprubart with important regulatory and financial advantages as it advances through clinical development for AMR in solid organ transplantation — a serious complication where the immune system attacks the donated organ. Currently, there are no FDA-approved therapies for this condition. The designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need in transplant medicine. Shares of Sanofi have outperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research An investigational IgG4 humanized monoclonal antibody, riliprubart is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system. The drug is currently being evaluated in a mid-stage study for AMR in kidney transplant recipients across two patient groups — those at risk of developing rejection and those already experiencing active AMR. Apart from AMR, Sanofi is also evaluating riliprubart in two late-stage studies — MOBILIZE and VITALIZE — for a rare neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP). While the MOBILIZE study targets patients for whom standard-of-care treatments do not work, the VITALIZE study compares the drug against intravenous immunoglobulin (IVIg). CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss. Notably, riliprubart has also received orphan drug designation in both the United States and EU for its prospective use in CIDP, highlighting its potential across multiple immune-mediated diseases. Sanofi currently carries a Zacks Rank #3 (Hold). Sanofi price | Sanofi Quote Some better-ranked stocks from the sector are Amarin Corporation AMRN, Immunocore IMCR and Agenus AGEN. While AMRN and IMCR sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Amarin's 2025 have improved from $5.01 to $2.50. Loss per share estimates for 2026 have narrowed from $3.84 to $1.78 during the same period. AMRN stock has surged nearly 65% year to date. Amarin's earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained nearly 9% year to date. Immunocore's earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%. In the past 60 days, Agenus' bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 83% so far this year. Agenus' earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Miami Herald
19 hours ago
- Miami Herald
An acid reflux drug got recalled. Company says bottles might have different meds
One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles. Teva Pharmaceuticals pulled lot No. 5420094 of 10 mg Metoclopramide tablets in 100-count bottles after 'a single 20 mg Torsemide tablet that does not belong was discovered in each of three individual sealed bottles of 10 mg Metoclopramide tablets.' It comes from the Teva press release posted to the company website that the FDA apparently missed when it stated 'press release not issued for this recall' under the press release URL part of the FDA's enforcement alert. Metoclopramide treats reflux symptoms in adults after failure of normal treatments. 'Torsemide is used to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease,' the Mayo Clinic said. READ MORE: Broward drug company recalls 3 eye drugs that might not be sterile The FDA classified this as a Class II recall, meaning problems caused by this mixup shouldn't last long, and there's a 'remote' chance of serious problems. '...the likelihood of an unintended drug reaction occurrence is remote/unlikely as Metoclopramide tablets will not be dispensed in the original packaging but will be divided at the pharmacy level,' Teva said. 'and be dispensed in smaller quantities for patient use, where the difference in tablets is likely to be noticed by the pharmacist.' 'Likely' although there's not much difference in how each medication looks. Teva says the 10 mg Metoclopramide tablets are white, round, dividing line on one side, '2203' above the divider on that side and 'TEVA' on the other side. The National Library of Medicine describes the 20 mg Torsemide tablets are white, round, dividing line on one side with '917' above the divider. The Metoclopramide tablets are 8 millimeters in size, while the Torsemide tablets are 10 millimeters. For instructions on how to return the recalled lot, which has an expiration date of 9/2027, go to Teva's online consumer recall letter. Direct questions about this recall to 888-838-2872, option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time to speak to a person. Voice mail works 24 hours a day. If you have a medical problem because you think a wayward Torsemide tablet was taken by a Metoclopramide user, call a medical professional. Then, notify the FDA MedWatch adverse event program. Third, call Teva at 888-838-2872, option 3, then option 4, Monday through Friday, 9 a.m. to 5 p.m., Eastern time, or email USMedInfo@
